# EDGAR Filing Document

**Accession Number:** 0001444307
**File Stem:** 0000000000-23-000911
**Filing Date:** 2023-1
**Character Count:** 5313
**Document Hash:** fa0d9319e3c7ce73e1e0a09c351c420d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-000911.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0000000000-23-000911

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230127

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ONCOSEC MEDICAL Inc
- **CENTRAL INDEX KEY:** 0001444307
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 980573252
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 820 BEAR TAVERN ROAD
- **CITY:** EWING
- **STATE:** NJ
- **ZIP:** 08628
- **BUSINESS PHONE:** (858) 210-7333

**MAIL ADDRESS:**
- **STREET 1:** 820 BEAR TAVERN ROAD
- **CITY:** EWING
- **STATE:** NJ
- **ZIP:** 08628

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NetVentory Solutions, Inc.
- **DATE OF NAME CHANGE:** 20080902

## Text-Extract

```

United States securities and exchange commission logo

                            January 27, 2023

       Robert Arch, Ph.D.
       Chief Executive Officer
       OncoSec Medical Inc.
       24 North Main Street
       Pennington, NJ 08534

                                                        Re: OncoSec Medical
Inc.
                                                            Form 10-K for
Fiscal Year Ended July 31, 2022
                                                            Filed October 31,
2022
                                                            File No. 000-54318

       Dear Robert Arch:

               We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comment. In our comment, we may ask
you to provide us
       with information so we may better understand your disclosure.

              Please respond to the comment within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comment applies to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to the comment, we may have additional comments.

       Form 10-K for Fiscal Year Ended July 31, 2022

       Notes to Consolidated Financial Statements
       Note 12 - Related Party Transactions, page F-24

   1.                                                   Please explain the
current status of the license and services agreements with CGP, as
                                                        disclosed in Note 10 of
your Form 10-K for the fiscal year ended July 31, 2020. Revise
                                                        your disclosure
accordingly.
              In closing, we remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
       absence of action by the staff.
 Robert Arch, Ph.D.
OncoSec Medical Inc.
January 27, 2023
Page 2

      You may contact Frank Wyman at 202-551-3660 or Angela Connell at 202-551-
3426 with any questions.

FirstName LastNameRobert Arch, Ph.D.                  Sincerely,
Comapany NameOncoSec Medical Inc.
                                                      Division of Corporation
Finance
January 27, 2023 Page 2                               Office of Life Sciences
FirstName LastName

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

CORPORATION FINANCE

# UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 27, 2023

Robert Arch, Ph.D.  
Chief Executive Officer  
OncoSec Medical Inc.  
24 North Main Street  
Pennington, NJ 08534

**Re: OncoSec Medical Inc.**  
**Form 10-K for Fiscal Year Ended July 31, 2022**  
**Filed October 31, 2022**  
**File No. 000-54318**

Dear Robert Arch:

We have limited our review of your filing to the financial statements and related disclosures and have the following comment. In our comment, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response.

After reviewing your response to the comment, we may have additional comments.

Form 10-K for Fiscal Year Ended July 31, 2022

Notes to Consolidated Financial Statements

Note 12 - Related Party Transactions, page F-24

1. Please explain the current status of the license and services agreements with CGP, as disclosed in Note 10 of your Form 10-K for the fiscal year ended July 31, 2020. Revise your disclosure accordingly.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Robert Arch, Ph.D.
OncoSec Medical Inc.
January 27, 2023
Page 2

You may contact Frank Wyman at 202-551-3660 or Angela Connell at 202-551-3426 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences